‘Now is the time to review your business’
Major changes to the Pharmacy Business Ownership Act 2024 will have several impacts on Queensland pharmacy owners, writes Lachlan Ballinger In December 2023, the Queensland Government took a significant step …
Decoding data for success
Having data-informed marketing strategy and analysis is essential for getting the best outcomes, says Sarah Rendell When it comes to pharmacists and marketing, I often come across this common assumption …
May MIMS update
A look at some of the recent changes to the medicines landscape, with new products, indications and contraindications New Product Nelarabine (Nelarabine‑Reach) is a pro‑drug of the deoxyguanosine analogue ara‑G. …
Seven ways to get started in HMRs
You’re accredited and you’re keen to get started doing medicines reviews, but how do you actually go about it? Brett Currie, Karalyn Huxhagen and Angus Thompson have some pointers One …
Fringe Benefits Tax
Pharmacy owners need to be mindful of fringe benefits tax (FBT) when providing employees with incentives, writes Victoria Le With the current market of finding good employees and providing benefits …
Keeping up with credentialing
Current credentialing arrangements for pharmacists have been extended into 2025. Experts in the field present a primer for medication management reviews Authors: Amy Page, Deborah Hawthorne and Brooke Shelly Pharmacists …
Navigating the rental squeeze
You need to understand the impact of CPI on retail shop leases, says Phil Chapman, using insights from the March 2024 quarter The latest release from the Australian Bureau of …
60 day dispensing KPIs
Over six months have passed since the implementation of sixty-day dispensing. It’s time to start monitoring your pharmacy’s performance during the transition, says Victoria Le In a recent LinkedIn video, …
Transitions of care
Why pharmacists are a critical part of the aged care puzzle, say Fei Sim and Laetitia Hattingh With Australia’s ageing population and increased healthcare needs, the seamless transition between hospital, …
April MIMS update
We look at some of the recent changes to the medicines landscape, with new products, indications and contraindications New Products Fezolinetant (Veoza) is a nonhormonal selective NK3 receptor antagonist that …
Investment ratings houses cool on Sigma/CWH deal
Evidence is growing that some institutional advisors may be starting to grow wary of the CWH/Sigma deal, says Mike Taylor When financial advisers make investment recommendations to clients they are …
Improving your patient engagement and experience
Transformational vs transactional : how would your customers describe their visit to your pharmacy? Glenn Guilfoyle and Marta Stybowski break down the steps to ensuring a better patient experience One …